**Name of Journal: *World Journal of Obstetrics and Gynecology***

**ESPS Manuscript NO: 21143**

**Manuscript Type: REVIEW**

**Care of survivors of gynecologic cancers**

Walker AJ *et al.* Care of survivors of gynecologic cancers

**Alexandra J Walker, Isidore D Benrubi, Kristy K Ward**

**Alexandra J Walker, Isidore D Benrubi, Kristy K Ward,** Division of Gynecologic Oncology, Department of Obstetrics and Gynecology,University of Florida College of Medicine-Jacksonville, Jacksonville, FL 32209, United States

**Author contributions:** All authors contributed in conception, writing, and editing of this work.

**Conflict-of-interest** **statement:** All authors report no conflict of interest.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Correspondence to:** K**risty K Ward, MD,** Division of Gynecologic Oncology, Department of Obstetrics and Gynecology,University of Florida College of Medicine-Jacksonville, 653-1 W 8th Street, Jacksonville, FL 32209, United States. [kristy.kay.ward@gmail.com](mailto:Daniel.benrubi@jax.ufl.edu)

**Telephone:** +1-904-2443112

**Fax:** +1-904-2443658

**Received:** June 29, 2015

**Peer-review started:** July 3, 2015

**First decision:** September 30, 2015

**Revised:** January 29, 2016

**Accepted:** February 23, 2016

**Article in press:**

**Published online:**

**Abstract**

The number of cancer survivors is increasing and most healthcare providers will manage patients who have completed therapy for malignancy at some point. The care of survivors of gynecologic malignancies may seem daunting in a busy general gynecology practice. This paper intends to review the literature and suggest management of these women for the general gynecologist.

**Key words:** Survivorship; Gynecologic cancer; Cancer surveillance; Cancer survivor; Female reproductive malignancy

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** As the number of cancer survivors increases, the gynecologist will increasingly care for women with a history of cancers of the reproductive tract. This paper will review survivorship care of gynecologic cancer survivors in the benign gynecologist’s office.

Walker AJ, Benrubi ID, Ward KK. Care of survivors of gynecologic cancers. *World J Obstet Gynecol* 2016; In press

**INTRODUCTION**

Advances in cancer diagnosis and treatment have led to a steady increase in the number of cancer survivors, a population with unique physical, psychosocial and economic needs. In recent decades, coordinated efforts have focused on understanding this population and on enhancing the length and quality of life of survivors. In 1996 the National Cancer Institute created the Office of Cancer Survivorship, and in recent decades increasing research has investigated diverse aspects of survivorship[1–3].

An individual is considered a survivor from the time of cancer diagnosis for the remainder of his or her life. The survivorship experience can be divided into phases including an acute treatment phase, an intermediate survivor phase, and a long-term survivor phase. Caregivers are also included as survivors, as their lives may be affected significantly by others’ cancer diagnoses. General survivorship care encompasses surveillance of the primary malignancy, managing complications of the cancer or its treatment, risk reduction and screening for second malignancies, and assessment of overall quality of life and psychosocial well-being[1,3].

The number of gynecologic cancer survivors has grown substantially in recent decades, most notably amongst those diagnosed with early stage disease. In the United States there are currently an estimated 625000 survivors of endometrial cancer, 244000 survivors of cervical cancer, and nearly 200000 survivors of ovarian cancer, in total accounting for about 15% of all female cancer survivors[1]. As the number of cancer survivors increases, the general gynecologist can expect to care for women with a history of female genital cancers. Herein we will review literature relevant to gynecologic cancer survivors and offer practical guidance to the non-oncologist caring for these patients. After all, gynecologic cancers combined are the fourth most common cancer type amongst survivors after breast, prostate and colorectal cancers, and the second most common amongst women.

**EFFECTS OF GYNECOLOGICAL CANCER AND TREATMENT**

***Psychosocial issues***

Attempting to understand and address the psychosocial challenges faced by cancer survivors is an established and important aspect of survivorship care and research[3]. Proceeding with life after cancer can be a complicated, life-altering process. The psychological evolution that occurs during this process can result potentially in both positive and negative outcomes amongst survivors[4].

Struggles commonly described by cancer survivors include fear, uncertainty, anxiety, depression, insomnia, relationship challenges, employment discrimination, financial concerns, and loss of insurance[5-10]. Furthermore, due to disease and treatment specifics, gynecologic cancer survivors may frequently encounter issues with body image, sexuality, and fertility[11,12]. Compared to other populations of cancer survivors, relatively few studies have specifically investigated the long-term psychosocial outcomes and needs of gynecologic cancer survivors. Caution must be emphasized when generalizing amongst survivors as each population faces unique challenges and has specific supportive care needs.

It has been recognized that medical variables, while important, seem to play a lesser role than psychological adjustment in predicting long-term psychological health amongst survivors[8,13]. Studies have suggested that survivors with better social support systems experience less anxiety and depression[14,15], and that socioeconomic status may strongly contribute to overall wellbeing[16]. A recent longitudinal study investigating long-term survivors of gynecologic cancers revealed overall normal levels of quality of life and relationship adjustment, however increased levels of anxiety and post-traumatic stress disorder amongst survivors[8]. Overall, more research is needed in this area.

In general, cancer survivors as a whole have fortunately shown positive responses to psychosocial interventions[7]. Unfortunately, many survivors do not receive psychosocial care[17], representing missed opportunities. Thus, we recommend routine psychological screening and emphasize that screening should continue throughout a survivor’s life, as a longer survivorship period does not necessarily correlate with decreased psychosocial concerns[8]. There are multiple brief psychosocial distress scales available for rapid in-office screening[18]. When psychological issues are identified, we recommend either treating or promptly referring for treatment.

Other interventions that have been associated with psychosocial well-being include healthy lifestyle interventions and management of menopausal symptoms. We recommend encouraging healthy lifestyle choices including healthy eating, regular exercise, and good sleep. Regular physical activity may positively affect survivors’ psychosocial wellbeing and quality of life[19,20]. Menopausal symptoms, especially in premenopausal patients, have been associated with distress, depression, and sexual dysfunction[21]. While most gynecologic cancer survivors can be treated with hormone replacement therapy[22], consult with the patient’s oncologist if there is concern about tumor hormonal response. The American College of Obstetricians and Gynecologists also recommends several non-hormonal options for management of menopausal symptoms that may be of benefit to these women[23].

In addition, it is important to address survivors’ supportive care needs, as increased unmet needs correlate with increased distress and decreased quality of life[8]. Referral to a well-run local survivor support group may be helpful, and can often be located through local chapters of the American Cancer Society[24]. Relationship counseling may be beneficial, especially amongst younger survivors[9]. Finally, sexual dysfunction and infertility, to be discussed subsequently, may profoundly affect survivors’ psychological health and social wellbeing[11,21].

***Sexual health***

Amongst cancer survivors in general, sexual dysfunction has been broadly identified as a common and often untreated problem[25]. Women treated for gynecologic malignancies are at risk for sexual dysfunction due to the nature, location, and treatment of their disease. After all, patients with gynecological cancer often undergo pelvic surgery and/or pelvic radiation, which may have considerable effects on sexual function[26]. Research has indicated that sexual concerns amongst gynecologic cancer survivors may include physical, psychological, and social dysfunctions[6,11,12]. A recent abstract presented at the 2015 American Society of Clinical Oncologists found that young, premenopausal women, those who underwent chemotherapy, and those in committed relationships may be at greater risk for sexual dysfunction, and among those with sexual dysfunction, a greater decline in sexual activity was seen after cancer treatment[27].

Pelvic radiation therapy may contribute significantly to many of the physical effects described, including skin fibrosis, shortening and narrowing of the vagina, disruption in ovarian function and subsequent vaginal dryness, dyspareunia, and loss of interest in sexual activity[26,28-30]. Other concerns identified amongst gynecologic cancer survivors include altered body image, decreased libido, sexual performance anxiety, and perceived changes in partner interest[31-34].

When considering treatment options for cancer-related sexual dysfunction it is important to recognize that normal sexual functioning can vary markedly, and that sexual function may improve as time from treatment increases[25,35]. Therapies addressing sexual dysfunction may focus on physical or psychosocial components. Studies evaluating various interventions are few and have shown mixed results[36,37].

We recommend screening all gynecologic cancer survivors for sexual dysfunction and offering therapeutic suggestions to interested patients. Optimal evaluation and treatment often requires a multidisciplinary team. Physical concerns are often related to loss of ovarian function and anatomical changes resulting from treatment. Although conclusive evidence does not exist regarding the efficacy of vaginal dilator use[37], use of a graduated series of dilators with lubricant may improve vaginal compliance, dyspareunia, and sexual function. Vaginal dryness may be improved with use of a vaginal moisturizer or a local estrogen product[38]. We also recommend screening for underlying psychological disorders. In addition, relationship counseling or consultation with a sexual therapist may benefit some patients.

***Fertility implications***

While the majority of women diagnosed with gynecologic cancer are post-menopausal, a significant number are of reproductive age. Clinicians must be aware of the reproductive consequences of treatments, which can profoundly affect a woman’s reproductive potential and overall wellbeing. Studies have shown that women with absent or impaired fertility resulting from gynecologic cancer treatment may experience depression, grief and stress resulting from infertility[11,19].

Gynecologic cancers are treated with some combination of surgery, radiation, and chemotherapy, any of which may negatively affect fertility. While surgery may remove part or all of a woman’s reproductive organs, radiation and chemotherapy can significantly hinder ovarian function and subsequent ability to conceive. Pelvic irradiation and alkylating chemotherapeutic agents pose the greatest threats to ovarian function, but other chemotherapeutics may contribute. In addition, pelvic irradiation affects the uterus and may hinder pregnancy implantation and appropriate growth[39,40].

As fertility has emerged as such a significant quality of life issue amongst cancer survivors, fertility preservation in patients undergoing gynecologic cancer treatment is an emerging topic. Reproductive aged women with fertility desires and early stage endometrial, cervical, and ovarian cancers are increasingly being offered fertility-conserving treatment options[41-43]. The complicated medical, ethical, and legal details of such are beyond the scope of this article, however this trend will undoubtedly affect future gynecologic cancer survivors. Gynecologic cancer survivors with fertility concerns should be promptly evaluated by reproductive specialists in conjunction with their oncologists.

***Premature loss of ovarian function***

As discussed previously, premenopausal women may lose ovarian function as a result of gynecologic cancer treatment. While menopausal symptoms may be quite disruptive to a woman psychologically, sexually, and socially[21], early loss of ovarian function may also have significant long-term effects on cardiovascular function, bone health, neurological status, and overall wellbeing[44-47]. We recommend encouragement of healthy lifestyle habits, following with a primary care provider, and consideration of hormone replacement therapy when appropriate. Furthermore, it is important to regularly screen affected women for bone loss and encourage healthy eating, calcium supplementation, and regular weight-bearing exercise. Providers may refer to ACOG’s published recommendations for management of osteoporosis[48].

***Lymphedema***

Lower-extremity lymphedema is a late effect experienced by some gynecologic cancer survivors, especially those treated with surgery or radiation involving the pelvic or inguinal lymph nodes[49]. Onset may occur immediately after therapy or be delayed many years[50]. Patients with lymphedema may complain of pain, heaviness, fullness, a tight sensation, or decreased flexibility in an affected limb. Simple activities of daily living may be affected, and ambulation may be difficult[51]. Physical exam findings may include non-pitting edema[52], and magnetic resonance imaging techniques are increasingly being used to diagnose early lymphedema[53].

Risk factors for developing lower extremity lymphedema include the extent of surgery or radiation to lymph nodes, removal of the circumflex iliac lymph nodes, cellulitis, and delayed wound healing[52,53]. Lymphedema may be instigated by small traumas including cuts, bites, injections, and sunburns. It is important for patients with lymphedema to maintain good skin hygiene and to engage in simple, regular range of motion exercises[51]. Therapies which may help survivors suffering from lymphedema include: Lymphedema hosiery, manual massage, compression bandages, or consultation with a lymphedema therapist. Severe cases may require hospitalization and intravenous antibiotics[49,51-53]. Lymphedema therapists may be located on the Lymphology Association of North America’s website, <http://www.clt-lana.org>.

***Cognitive dysfunction***

Furthermore, cancer patients may suffer from cognitive dysfunction, which may persist long after completion of treatment. The individual patient, type of cancer, and variety of treatment all combine to influence a survivor’s cognitive state. Factors that may contribute to cognitive dysfunction include: Indirect effects of the cancer itself, brain metastases, chemotherapy, radiation therapy, medication effects, preexisting conditions and psychiatric issues[54]. Research exploring cognitive-related cancer dysfunction in survivors of gynecologic cancers is scant, as most literature in this area has focused on general or breast cancer survivors. However, cognitive decline has been identified amongst gynecologic cancer survivors and must be considered in survivor care plans[55,56].

Interestingly, the cognitive deficits commonly described by survivors tend to differ from those of neurodegenerative diseases. Cancer patients and survivors often describe problems with organization, attention, memory, multitasking, and efficiency, often causing problems with occupational or social responsibilities[57,58]. Standard tests such as the Mini Mental Status Exam are often not sensitive enough to detect the subtle cognitive deficits experienced by survivors, and perceived cognitive decline may be considered reason to explore potential intervention[56].

When assessing cancer survivors with perceived cognitive dysfunction it is important to address and treat fatigue, assess psychological health, assess for anemia, and encourage healthy lifestyle habits. Potential interventions include cognitive behavior therapy, coping strategies such as assisted technology or memory aids, compensatory strategy training, stress management, and energy management[56,59,60]. It is also important to remember that a new cognitive deficit in a cancer survivor could be an indication of recurrence and requires prompt evaluation.

**SURVIVORSHIP ISSUES BY GYNECOLOGIC CANCER TYPE**

***Endometrial cancer***

Endometrial cancer is both the most common and the most curable type of gynecologic cancer[61]. Fortunately, among the nearly 55000 women expected to be diagnosed with endometrial cancer in 2015, most will be diagnosed with early-stage disease and given an excellent prognosis. Approximately 67% of women have localized disease at diagnosis, with estimated 5-year survival at 95%. Overall 5-year survival for endometrial cancer patients is approximately 82%, the highest amongst gynecologic cancers[62]. Thus it is important to understand and address the unique needs of this population.

When caring for endometrial cancer survivors, providers must address adverse treatment effects and screen for disease recurrence and second primary cancers. Equally important is addressing cardiovascular health and lifestyle factors. Overall morbidity amongst endometrial cancer survivors is high, despite favorable cancer prognoses. This has been attributed to the strong association of endometrial cancer with obesity and its related co-morbidities including hypertension, diabetes, metabolic syndrome, and pulmonary disease[63,64]. Women with endometrial cancer are more likely to die from cardiovascular disease than from cancer[65], and obesity has been associated with increased morbidity and decreased quality of life in survivors[66,67]. Recent studies evaluating lifestyle programs that target endometrial cancer survivors have shown that various interventions may be able to increase physical activity levels, improve dietary habits, and influence weight loss in these patients[68-73]. Further study is needed in this area.

While the majority of women diagnosed with endometrial cancer are postmenopausal, an estimated 25% are premenopausal. Since 1988 the standard treatment for endometrial cancer has been hysterectomy and bilateral salpingoophorectomy, making loss of ovarian function amongst premenopausal women treated for endometrial cancer an important issue[61,74]. These women experience abrupt onset menopausal symptoms, which may exacerbate psychological difficulties and sexual dysfunction.

Traditionally, estrogen replacement therapy in survivors of endometrial cancer has been avoided since most endometrial cancers are estrogen dependent. Review of limited evidence suggests that estrogen replacement may be a reasonable option in premenopausal patients with a history of early-stage disease, and may be considered with appropriate risk-benefit counseling and oncology consultation[75,76]. Of note, some premenopausal women with endometrial cancer are choosing fertility preserving or ovarian preserving therapies[77,78]. The details of such treatments are beyond the scope of this review, however may influence the future composition of this population.

Furthermore, survivors of endometrial cancer are at increased risk for multiple subsequent cancers[64,79,80]. Breast and colon cancers are the most commonly identified second primary cancers in endometrial cancer survivors and require regular screening[80]. Patients with endometrial cancer may have a genetic predisposition for development of other cancers, such as in Lynch syndrome, and should be offered genetic screening when personal or family history indicates[80,81].

When caring for endometrial cancer survivors we recommend: Yearly pelvic exams, imaging as clinically indicated, regular screening for second primary cancers, and genetic testing when indicated. We also recommend routine assessment of psychosocial wellbeing, sexual health, and adverse treatment-related effects, accompanied by treatment or referral as indicated. Furthermore, we recommend medical optimization of cardiovascular health and increased emphasis on healthy lifestyle choices. At minimum, obese endometrial cancer survivors should receive physician counseling regarding weight loss, physical activity, and healthy eating. Ideally these patients should be referred to weight loss and lifestyle intervention programs available within their medical communities. Finally, in order to provide optimal care to endometrial cancer survivors we recommend that these women follow with a gynecologist or gynecologic-oncologist as well as a primary care specialist familiar with the needs of this population.

***Ovarian cancer***

Ovarian cancer is the second most common gynecologic cancer in the United States, with an estimated 21000 diagnoses expected in 2015. Significant survival differences exist between women diagnosed with early stage disease and those diagnosed with advanced disease. Unfortunately, 60% have distant spread at diagnosis and 5-year survival at 28%. However women diagnosed with localized or regional spread have better prognoses with 5-year survival at 92% and 73%, respectively[82,83].

Importantly, notable survival differences exist between women diagnosed with epithelial ovarian cancer and those diagnosed with ovarian germ cell tumors. While the former are generally diagnosed at an advanced stage with limited survival potential, many women diagnosed with germ cell tumors face favorable prognoses. In these women, who are often diagnosed at a young age and make up a small proportion of overall ovarian cancer diagnoses, survival is common and treatment may frequently induce concerns related to fertility, premature loss of ovarian function, and disease recurrence[83-85].

Ovarian cancer is generally treated with surgery and/or chemotherapy, and survivors may additionally experience neuropathy, cognitive decline, psychosocial difficulties, and sexual dysfunction[55,86-88]. Fear of recurrence is of particular concern in this population and may contribute to significant anxiety and decreased quality of life. Studies have shown that psychosocial wellbeing can have the greatest influence on overall quality of life amongst ovarian cancer survivors[89]. Adequately powered longitudinal studies are needed to further qualify, quantify, and assess the specific survivorship needs of this population.

When providing care to survivors or ovarian cancer, we recommend: Routine exams at least yearly and imaging as clinically indicated. Evaluation of tumor markers should be directed by the patient’s oncologist. We recommend screening for neuropathy and cognitive difficulties, psychological and sexual dysfunction, and referral for treatment when indicated. Similar to endometrial cancer survivors, survivors of ovarian cancer benefit from a healthy diet, maintaining supportive relationships, regular physical activity and maintaining a healthy weight. Survivors may carry BRCA1, BRCA2, or HNPCC mutations, and should be screened for such based on personal and family histories[90].

***Cervical cancer***

Cervical cancer is the third most common gynecologic cancer in the United States. Its incidence has decreased markedly in recent decades with the introduction of widespread screening and treatment of pre-invasive disease. The recent introduction of the HPV vaccine will hopefully further decrease cervical cancer incidence in coming decades[91].

Despite improved screening, an estimated 13000 women are expected to be diagnosed with this malignancy in 2015. Nearly half of these women will be diagnosed with local disease with 5-year survival at 90%. Overall, 5-year survival amongst cervical cancer patients is estimated at 68%[92]. Cervical cancer affects younger women when compared with other gynecologic cancers, with mean age at time of diagnosis approximately 50 years, resulting in longer post-treatment life expectancies. In addition, women of lower socioeconomic status and women of minority or immigrant groups are more likely to develop invasive cervical cancer[93,94].

Women diagnosed with very early stage disease are often treated exclusively with surgery. More advanced disease is generally treated with radiation and chemotherapy. Survivors may suffer from psychosocial difficulties, sexual dysfunction, long-term treatment side effects, and second primary malignancies. Studies have suggested that survivors who received treatment with radiation therapy are at increased risk of suffering from long-term physical effects and sexual dysfunction when compared to those treated with radical surgery alone[93,95,96].

Premenopausal women treated for cervical cancer may suffer from premature ovarian failure as a result of treatment. Estrogen replacement therapy is generally considered to be appropriate in this population and may be considered[22,97]. Women who have not completed childbearing at the time of diagnosis may suffer from psychological and social difficulties resulting from treatment-induced infertility. Fortunately, fertility preservation is increasingly being offered to women with very early stage invasive disease[98-100], and ovarian-preserving efforts including pre-treatment ovarian transposition have been investigated with promising results[101,102].

Furthermore, women with a history of cervical cancer are at increased risk of developing subsequent cancers of the vulva, vagina, and rectum as well as tobacco-related malignancies including lung, esophageal, stomach, urogenital, pancreatic, and leukemia in those with a tobacco use history[103-105]. Thus, it is important to screen for potential second malignancies and to routinely address tobacco use.

When providing care to cervical cancer survivors we recommend: yearly pelvic exams with pap screening, imaging as clinically indicated, and routine screening for second primary cancers. Furthermore, we encourage healthy lifestyle choices and regular tobacco prevention and cessation efforts, including referral to cessation programs for motivated patients. It is important to recognize that many of these patients may suffer from long-term psychological issues or have severe physical effects from cancer treatment. We also recommend educating these survivors on the importance of encouraging their family and community members to undergo routine cervical screening.

***Vulvar cancer***

Vulvar cancer is the fourth most common gynecologic cancer, with approximately 5000 women expected to be diagnosed in 2015[106]. Vulvar cancer diagnoses occur most frequently in women between the ages of 65-75, however vulvar cancer has increased in younger populations, likely due to increasing HPV prevalence[107]. As with cervical cancer, the introduction of the HPV vaccine will hopefully decrease vulvar cancer incidence in the coming decades[92]. Women with vulvar cancer are generally treated with pelvic surgery and/or radiation therapy[108].

Overall the literature assessing survivorship issues specific to vulvar cancer is limited. Patients treated with extensive surgery or radiation therapy seem to be at risk for decreased quality of life, including sexual dysfunction and psychosocial difficulties[108-110]. These patients may suffer from skin changes including changes in skin texture and color, thickening, contractures, fibrosis, decreased clitoral sensation, and painful intercourse. Patients treated with extensive lymph node surgery or radiation therapy often suffer from chronic lymphedema[111].

As vulvar cancer has increased among younger women who often present with less advanced disease, a trend toward less radical surgery has emerged. Wide local excision has been associated with higher quality of life amongst survivors when compared to radical vulvectomy[109], and sophisticated sentinel node mapping techniques are decreasing the need for radical lymph node surgery and the associated risk of lymphedema[112]. Overall, more research is needed to define and best meet the evolving needs of vulvar cancer survivors.

When treating these patients we recommend: Routine pelvic exams and screening for disease recurrence, as well as routine guideline-recommended screening for other cancers. In tobacco users we recommend an emphasis on cessation. Finally, we recommend approaching these patients with awareness that mental health or sexual counseling may be indicated, especially in patients with a history of extensive pelvic surgery or radiation therapy.

**CONCLUSION**

The number of gynecologic cancer survivors is expected to continue to increase in coming decades. While further research is warranted to better understand and meet the needs of this population, there are many things that the general gynecologists can do to manage the survivorship care of these women. Attention to the unique psychosocial symptoms, treatment related sequella, cancer type specific issues, and management of general health maintenance and other health issues would improve the health and quality of life of gynecologic cancer survivors.

**REFERENCES**

1 **American Cancer Society**. Cancer Treatment and Survivorship Facts & Figures 2014-2015. Atlanta: American Cancer Society; 2014. Available from: URL: www.cancer.org/research/cancerfactsstatistics/survivor-facts-figures

2 **National Institute of Cancer, Office of Cancer Survivorship**. Definitions, Statistics, and Graphs. [accessed 2015 Jun 1]. Available from: URL: http://cancercontrol.cancer.gov/ocs/statistics/statistics.html

3 **National Research Council**. From Cancer Patient to Cancer Survivor: Lost in Transition. Washington, DC: The National Academies Press, 2005. Available from: URL: http://iom.nationalacademies.org/Reports/2005/From-Cancer-Patient-to-Cancer-Survivor-Lost-in-Transition.aspx?utm\_source=Twitter&utm\_medium=Tweet&utm\_campaign=Hootsuite

4 **Thornton AA**, Perez MA. Posttraumatic growth in prostate cancer survivors and their partners. *Psychooncology* 2006; **15**: 285-296 [PMID: 16035136]

5 **Wenzel LB**, Donnelly JP, Fowler JM, Habbal R, Taylor TH, Aziz N, Cella D. Resilience, reflection, and residual stress in ovarian cancer survivorship: a gynecologic oncology group study. *Psychooncology* 2002; **11**: 142-153 [PMID: 11921330]

6 **Roland KB**, Rodriguez JL, Patterson JR, Trivers KF. A literature review of the social and psychological needs of ovarian cancer survivors. *Psychooncology* 2013; **22**: 2408-2418 [PMID: 23760742 DOI: 10.1002/pon.3322]

7 **Meyer TJ**, Mark MM. Effects of psychosocial interventions with adult cancer patients: a meta-analysis of randomized experiments. *Health Psychol* 1995; **14**: 101-108 [PMID: 7789344]

8 **Hodgkinson K**, Butow P, Fuchs A, Hunt GE, Stenlake A, Hobbs KM, Brand A, Wain G. Long-term survival from gynecologic cancer: psychosocial outcomes, supportive care needs and positive outcomes. *Gynecol Oncol* 2007; **104**: 381-389 [PMID: 17027072]

9 **Kirchhoff AC**, Yi J, Wright J, Warner EL, Smith KR. Marriage and divorce among young adult cancer survivors. *J Cancer Surviv* 2012; **6**: 441-450 [PMID: 22956304 DOI: 10.1007/s11764-012-0238-6]

10 **Bodurka DC**, Sun CC, Frumovitz MM. Quality of life in cervix cancer survivors--what matters the most in the long-term? *Gynecol Oncol* 2005; **97**: 307-309 [PMID: 15863122]

11 **Carter J**, Raviv L, Applegarth L, Ford JS, Josephs L, Grill E, Sklar C, Sonoda Y, Baser RE, Barakat RR. A cross-sectional study of the psychosexual impact of cancer-related infertility in women: third-party reproductive assistance. *J Cancer Surviv* 2010; **4**: 236-246 [PMID: 20373042 DOI: 10.1007/s11764-010-0121-2]

12 **Abbott-Anderson K**, Kwekkeboom KL. A systematic review of sexual concerns reported by gynecological cancer survivors. *Gynecol Oncol* 2012; **124**: 477-489 [PMID: 22134375 DOI: 10.1016/j.ygyno.2011.11.030]

13 **Carver CS**, Smith RG, Petronis VM, Antoni MH. Quality of life among long-term survivors of breast cancer: Different types of antecedents predict different classes of outcomes. *Psychooncology* 2006; **15**: 749-758 [PMID: 16304622]

14 **Kimmel M**, Fairbairn M, Giuntoli R, Jernigan A, Belozer A, Payne J, Swartz K, Díaz-Montes TP. The importance of social support for women with elevated anxiety undergoing care for gynecologic malignancies. *Int J Gynecol Cancer* 2014; **24**: 1700-1708 [PMID: 25340295 DOI: 10.1097/IGC.0000000000000285]

15 **Carpenter KM**, Fowler JM, Maxwell GL, Andersen BL. Direct and buffering effects of social support among gynecologic cancer survivors. *Ann Behav Med* 2010; **39**: 79-90 [PMID: 20151235 DOI: 10.1007/s12160-010-9160-1]

16 **Greenwald HP**, McCorkle R, Baumgartner K, Gotay C, Neale AV. Quality of life and disparities among long-term cervical cancer survivors. *J Cancer Surviv* 2014; **8**: 419-426 [PMID: 24706363 DOI: 10.1007/s11764-014-0352-8]

17 **Forsythe LP**, Kent EE, Weaver KE, Buchanan N, Hawkins NA, Rodriguez JL, Ryerson AB, Rowland JH. Receipt of psychosocial care among cancer survivors in the United States. *J Clin Oncol* 2013; **31**: 1961-1969 [PMID: 23610114 DOI: 10.1200/JCO.2012.46.2101]

18 **National Cancer Institute**. Adjustment to Cancer: Anxiety and Distress–for health professionals (PDQ®). [accessed 2015 Jun 28]. Available from: URL: http://www.cancer.gov/about-cancer/coping/feelings/anxiety-distress-hp-pdq#link/stoc\_h2\_3

19 **Stevinson C**, Faught W, Steed H, Tonkin K, Ladha AB, Vallance JK, Capstick V, Schepansky A, Courneya KS. Associations between physical activity and quality of life in ovarian cancer survivors. *Gynecol Oncol* 2007; **106**: 244-250 [PMID: 17493671]

20 **Crawford JJ**, Vallance JK, Holt NL, Courneya KS. Associations between exercise and posttraumatic growth in gynecologic cancer survivors. *Support Care Cancer* 2015; **23**: 705-714 [PMID: 25172310 DOI: 10.1007/s00520-014-2410-1]

21 **Carter J**, Chi DS, Brown CL, Abu-Rustum NR, Sonoda Y, Aghajanian C, Levine DA, Baser RE, Raviv L, Barakat RR. Cancer-related infertility in survivorship. *Int J Gynecol Cancer* 2010; **20**: 2-8 [PMID: 20130497 DOI: 10.1111/IGC.0b013e3181bf7d3f]

22 **Biliatis I**, Thomakos N, Rodolakis A, Akrivos N, Zacharakis D, Antsaklis A. Safety of hormone replacement therapy in gynaecological cancer survivors. *J Obstet Gynaecol* 2012; **32**: 321-325 [PMID: 22519472 DOI: 10.3109/01443615.2012.668579]

23 **American College of Obstetricians and Gynecologists**. ACOG Practice Bulletin No. 141: management of menopausal symptoms. *Obstet Gynecol* 2014; **123**: 202-216 [PMID: 24463691 DOI: 10.1097/01.AOG.0000441353.20693.78]

24 **Sanson-Fisher R**, Girgis A, Boyes A, Bonevski B, Burton L, Cook P. The unmet supportive care needs of patients with cancer. Supportive Care Review Group. *Cancer* 2000; **88**: 226-237 [PMID: 10618627]

25 **Sadovsky R**, Basson R, Krychman M, Morales AM, Schover L, Wang R, Incrocci L. Cancer and sexual problems. *J Sex Med* 2010; **7**: 349-373 [PMID: 20092444 DOI: 10.1111/j.1743-6109.2009.01620.x]

26 **Donovan KA**, Taliaferro LA, Alvarez EM, Jacobsen PB, Roetzheim RG, Wenham RM. Sexual health in women treated for cervical cancer: characteristics and correlates. *Gynecol Oncol* 2007; **104**: 428-434 [PMID: 17005248]

27 **Guntupalli S**, Flink D, Sheeder J. Sexual and marital dysfunction in women with gynecologic cancer: A multi-institutional, cross-sectional trial. *J Clin Oncol* 2015; **33**: (suppl; abstr 9592)

28 **Aerts L**, Enzlin P, Verhaeghe J, Vergote I, Amant F. Sexual and psychological functioning in women after pelvic surgery for gynaecological cancer. *Eur J Gynaecol Oncol* 2009; **30**: 652-656 [PMID: 20099497]

29 **Bergmark K**, Avall-Lundqvist E, Dickman PW, Henningsohn L, Steineck G. Vaginal changes and sexuality in women with a history of cervical cancer. *N Engl J Med* 1999; **340**: 1383-1389 [PMID: 10228188]

30 **Amsterdam A**, Krychman ML. Sexual dysfunction in patients with gynecologic neoplasms: a retrospective pilot study. *J Sex Med* 2006; **3**: 646-649 [PMID: 16776780]

31 **Carmack Taylor CL**, Basen-Engquist K, Shinn EH, Bodurka DC. Predictors of sexual functioning in ovarian cancer patients. *J Clin Oncol* 2004; **22**: 881-889 [PMID: 14990644]

32 **Corney RH**, Crowther ME, Everett H, Howells A, Shepherd JH. Psychosexual dysfunction in women with gynaecological cancer following radical pelvic surgery. *Br J Obstet Gynaecol* 1993; **100**: 73-78 [PMID: 8427843]

33 **Juraskova I**, Butow P, Robertson R, Sharpe L, McLeod C, Hacker N. Post-treatment sexual adjustment following cervical and endometrial cancer: a qualitative insight. *Psychooncology* 2003; **12**: 267-279 [PMID: 12673810]

34 **Lindau ST**, Gavrilova N, Anderson D. Sexual morbidity in very long term survivors of vaginal and cervical cancer: a comparison to national norms. *Gynecol Oncol* 2007; **106**: 413-418 [PMID: 17582473]

35 **Vaz AF**, Pinto-Neto AM, Conde DM, Costa-Paiva L, Morais SS, Pedro AO, Esteves SB. Quality of life and menopausal and sexual symptoms in gynecologic cancer survivors: a cohort study. *Menopause* 2011; **18**: 662-669 [PMID: 21471827 DOI: 10.1097/gme.0b013e3181ffde7f]

36 **Brotto LA**, Heiman JR, Goff B, Greer B, Lentz GM, Swisher E, Tamimi H, Van Blaricom A. A psychoeducational intervention for sexual dysfunction in women with gynecologic cancer. *Arch Sex Behav* 2008; **37**: 317-329 [PMID: 17680353]

37 **Miles T**, Johnson N. Vaginal dilator therapy for women receiving pelvic radiotherapy. *Cochrane Database Syst Rev* 2014; **9**: CD007291 [PMID: 25198150 DOI: 10.1002/14651858.CD007291.pub3]

38 **Carter J**, Goldfrank D, Schover LR. Simple strategies for vaginal health promotion in cancer survivors. *J Sex Med* 2011; **8**: 549-559 [PMID: 20722792 DOI: 10.1111/j.1743-6109.2010.01988.x]

39 **Stroud JS**, Mutch D, Rader J, Powell M, Thaker PH, Grigsby PW. Effects of cancer treatment on ovarian function. *Fertil Steril* 2009; **92**: 417-427 [PMID: 18774559 DOI: 10.1016/j.fertnstert.2008.07.1714]

40 **Noyes N**, Knopman JM, Long K, Coletta JM, Abu-Rustum NR. Fertility considerations in the management of gynecologic malignancies. *Gynecol Oncol* 2011; **120**: 326-333 [PMID: 20943258 DOI: 10.1016/j.ygyno.2010.09.012]

41 **Ditto A**, Martinelli F, Bogani G, Fischetti M, Di Donato V, Lorusso D, Raspagliesi F. Fertility-sparing surgery in early-stage cervical cancer patients: oncologic and reproductive outcomes. *Int J Gynecol Cancer* 2015; **25**: 493-497 [PMID: 25628110 DOI: 10.1097/IGC.0000000000000371]

42 **Ditto A**, Martinelli F, Lorusso D, Haeusler E, Carcangiu M, Raspagliesi F. Fertility sparing surgery in early stage epithelial ovarian cancer. *J Gynecol Oncol* 2014; **25**: 320-327 [PMID: 25142621 DOI: 10.3802/jgo.2014.25.4.320]

43 **Koskas M**, Uzan J, Luton D, Rouzier R, Daraï E. Prognostic factors of oncologic and reproductive outcomes in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma: systematic review and meta-analysis. *Fertil Steril* 2014; **101**: 785-794 [PMID: 24388202 DOI: 10.1016/j.fertnstert.2013.11.028]

44 **Stavraka C**, Maclaran K, Gabra H, Agarwal R, Ghaem-Maghami S, Taylor A, Dhillo WS, Panay N, Blagden SP. A study to evaluate the cause of bone demineralization in gynecological cancer survivors. *Oncologist* 2013; **18**: 423-429 [PMID: 23363808 DOI: 10.1634/theoncologist.2012-0416]

45 **Shuster LT**, Rhodes DJ, Gostout BS, Grossardt BR, Rocca WA. Premature menopause or early menopause: long-term health consequences. *Maturitas* 2010; **65**: 161-166 [PMID: 19733988 DOI: 10.1016/j.maturitas.2009.08.003]

46 **Atsma F**, Bartelink ML, Grobbee DE, van der Schouw YT. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. *Menopause* 2006; **13**: 265-279 [PMID: 16645540]

47 **de Kleijn MJ**, van der Schouw YT, Verbeek AL, Peeters PH, Banga JD, van der Graaf Y. Endogenous estrogen exposure and cardiovascular mortality risk in postmenopausal women. *Am J Epidemiol* 2002; **155**: 339-345 [PMID: 11836198]

48 **American College of Obstetricians and Gynecologists**. ACOG Practice Bulletin N. 129. Osteoporosis. *Obstet Gynecol* 2012; **120**: 718-734 [PMID: 22914492 DOI: 10.1097/AOG.0b013e31826dc446]

49 **Beesley V**, Janda M, Eakin E, Obermair A, Battistutta D. Lymphedema after gynecological cancer treatment: prevalence, correlates, and supportive care needs. *Cancer* 2007; **109**: 2607-2614 [PMID: 17474128]

50 **Hareyama H**, Hada K, Goto K, Watanabe S, Hakoyama M, Oku K, Hayakashi Y, Hirayama E, Okuyama K. Prevalence, classification, and risk factors for postoperative lower extremity lymphedema in women with gynecologic malignancies: a retrospective study. *Int J Gynecol Cancer* 2015; **25**: 751-757 [PMID: 25723779]

51 **International Society of Lymphology**. The diagnosis and treatment of peripheral lymphedema: 2013 Consensus Document of the International Society of Lymphology. *Lymphology* 2013; **46**: 1-11 [PMID: 23930436]

52 **Brennan MJ**, Miller LT. Overview of treatment options and review of the current role and use of compression garments, intermittent pumps, and exercise in the management of lymphedema. *Cancer* 1998; **83**: 2821-2827 [PMID: 9874405]

53 **Abu-Rustum NR**, Barakat RR. Observations on the role of circumflex iliac node resection and the etiology of lower extremity lymphedema following pelvic lymphadenectomy for gynecologic malignancy. *Gynecol Oncol* 2007; **106**: 4-5 [PMID: 17477957]

54 **Andreotti C**, Root JC, Ahles TA, McEwen BS, Compas BE. Cancer, coping, and cognition: a model for the role of stress reactivity in cancer-related cognitive decline. *Psychooncology* 2015; **24**: 617-623 [PMID: 25286084 DOI: 10.1002/pon.3683]

55 **Correa DD**, Zhou Q, Thaler HT, Maziarz M, Hurley K, Hensley ML. Cognitive functions in long-term survivors of ovarian cancer. *Gynecol Oncol* 2010; **119**: 366-369 [PMID: 20630576 DOI: 10.1016/j.ygyno.2010.06.023]

56 **Sleight A**. Coping with cancer-related cognitive dysfunction: a scoping review of the literature. *Disabil Rehabil* 2016; **38**: 400-408 [PMID: 25885669]

57 **Falleti MG**, Sanfilippo A, Maruff P, Weih L, Phillips KA. The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. *Brain Cogn* 2005; **59**: 60-70 [PMID: 15975700]

58 **Boykoff N**, Moieni M, Subramanian SK. Confronting chemobrain: an in-depth look at survivors' reports of impact on work, social networks, and health care response. *J Cancer Surviv* 2009; **3**: 223-232 [PMID: 19760150 DOI: 10.1007/s11764-009-0098-x]

59 **Ferguson RJ**, McDonald BC, Rocque MA, Furstenberg CT, Horrigan S, Ahles TA, Saykin AJ. Development of CBT for chemotherapy-related cognitive change: results of a waitlist control trial. *Psychooncology* 2012; **21**: 176-186 [PMID: 22271538 DOI: 10.1002/pon.1878]

60 **Goedendorp MM**, Knoop H, Gielissen MF, Verhagen CA, Bleijenberg G. The effects of cognitive behavioral therapy for postcancer fatigue on perceived cognitive disabilities and neuropsychological test performance. *J Pain Symptom Manage* 2014; **47**: 35-44 [PMID: 23707383 DOI: 10.1016/j.jpainsymman.2013.02.014]

61 Practice Bulletin No. 149: Endometrial cancer. *Obstet Gynecol* 2015; **125**: 1006-1026 [PMID: 25798986 DOI: 10.1097/01.AOG.0000462977.61229.de]

62 NIH Surveillance Research Program. SEER Stat Fact Sheets – Cancer of the Endometrium. [accessed 2015 May 31]. Available from: URL: http://seer.cancer.gov/statfacts/html/corp.html

63 **von Gruenigen VE**, Tian C, Frasure H, Waggoner S, Keys H, Barakat RR. Treatment effects, disease recurrence, and survival in obese women with early endometrial carcinoma : a Gynecologic Oncology Group study. *Cancer* 2006; **107**: 2786-2791 [PMID: 17096437]

64 **Bjørge T**, Stocks T, Lukanova A, Tretli S, Selmer R, Manjer J, Rapp K, Ulmer H, Almquist M, Concin H, Hallmans G, Jonsson H, Stattin P, Engeland A. Metabolic syndrome and endometrial carcinoma. *Am J Epidemiol* 2010; **171**: 892-902 [PMID: 20219764 DOI: 10.1093/aje/kwq006]

65 **Ward KK**, Shah NR, Saenz CC, McHale MT, Alvarez EA, Plaxe SC. Cardiovascular disease is the leading cause of death among endometrial cancer patients. *Gynecol Oncol* 2012; **126**: 176-179 [PMID: 22507532 DOI: 10.1016/j.ygyno.2012.04.013]

66 **Courneya KS**, Karvinen KH, Campbell KL, Pearcey RG, Dundas G, Capstick V, Tonkin KS. Associations among exercise, body weight, and quality of life in a population-based sample of endometrial cancer survivors. *Gynecol Oncol* 2005; **97**: 422-430 [PMID: 15863140]

67 **Smits A**, Lopes A, Das N, Bekkers R, Galaal K. The impact of BMI on quality of life in obese endometrial cancer survivors: does size matter? *Gynecol Oncol* 2014; **132**: 137-141 [PMID: 24262880 DOI: 10.1016/j.ygyno.2013.11.018]

68 **Basen-Engquist K**, Carmack C, Brown J, Jhingran A, Baum G, Song J, Scruggs S, Swartz MC, Cox MG, Lu KH. Response to an exercise intervention after endometrial cancer: differences between obese and non-obese survivors. *Gynecol Oncol* 2014; **133**: 48-55 [PMID: 24680591 DOI: 10.1016/j.ygyno.2014.01.025]

69 **von Gruenigen VE**, Courneya KS, Gibbons HE, Kavanagh MB, Waggoner SE, Lerner E. Feasibility and effectiveness of a lifestyle intervention program in obese endometrial cancer patients: a randomized trial. *Gynecol Oncol* 2008; **109**: 19-26 [PMID: 18243282 DOI: 10.1016/j.ygyno.2007.12.026]

70 **von Gruenigen VE**, Gibbons HE, Kavanagh MB, Janata JW, Lerner E, Courneya KS. A randomized trial of a lifestyle intervention in obese endometrial cancer survivors: quality of life outcomes and mediators of behavior change. *Health Qual Life Outcomes* 2009; **7**: 17 [PMID: 19243603 DOI: 10.1186/1477-7525-7-17]

71 **von Gruenigen VE**, Waggoner SE, Frasure HE, Kavanagh MB, Janata JW, Rose PG, Courneya KS, Lerner E. Lifestyle challenges in endometrial cancer survivorship. *Obstet Gynecol* 2011; **117**: 93-100 [PMID: 21173649 DOI: 10.1097/AOG.0b013e31820205b3]

72 **von Gruenigen V**, Frasure H, Kavanagh MB, Janata J, Waggoner S, Rose P, Lerner E, Courneya KS. Survivors of uterine cancer empowered by exercise and healthy diet (SUCCEED): a randomized controlled trial. *Gynecol Oncol* 2012; **125**: 699-704 [PMID: 22465522 DOI: 10.1016/j.ygyno.2012.03.042]

73 **McCarroll ML**, Armbruster S, Frasure HE, Gothard MD, Gil KM, Kavanagh MB, Waggoner S, von Gruenigen VE. Self-efficacy, quality of life, and weight loss in overweight/obese endometrial cancer survivors (SUCCEED): a randomized controlled trial. *Gynecol Oncol* 2014; **132**: 397-402 [PMID: 24369301 DOI: 10.1016/j.ygyno.2013.12.023]

74 **Sorosky JI**. Endometrial cancer. *Obstet Gynecol* 2008; **111**: 436-447 [PMID: 18238985 DOI: 10.1097/AOG.0b013e318162f690]

75 **Chapman JA**, DiSaia PJ, Osann K, Roth PD, Gillotte DL, Berman ML. Estrogen replacement in surgical stage I and II endometrial cancer survivors. *Am J Obstet Gynecol* 1996; **175**: 1195-1200 [PMID: 8942487]

76 **Barakat RR**, Bundy BN, Spirtos NM, Bell J, Mannel RS. Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study. *J Clin Oncol* 2006; **24**: 587-592 [PMID: 16446331]

77 **Erkanli S**, Ayhan A. Fertility-sparing therapy in young women with endometrial cancer: 2010 update. *Int J Gynecol Cancer* 2010; **20**: 1170-1187 [PMID: 21495221]

78 **Sun C**, Chen G, Yang Z, Jiang J, Yang X, Li N, Zhou B, Zhu T, Wei J, Weng D, Ma D, Wang C, Kong B. Safety of ovarian preservation in young patients with early-stage endometrial cancer: a retrospective study and meta-analysis. *Fertil Steril* 2013; **100**: 782-787 [PMID: 23830105 DOI: 10.1016/j.fertnstert.2013.05.032]

79 **Hemminki K**, Aaltonen L, Li X. Subsequent primary malignancies after endometrial carcinoma and ovarian carcinoma. *Cancer* 2003; **97**: 2432-2439 [PMID: 12733142]

80 **Re A**, Taylor TH, DiSaia PJ, Anton-Culver H. Risk for breast and colorectal cancers subsequent to cancer of the endometrium in a population-based case series. *Gynecol Oncol* 1997; **66**: 255-257 [PMID: 9264572]

81 **Uccella S**, Cha SS, Melton LJ, Bergstralh EJ, Boardman LA, Keeney GL, Podratz KC, Ciancio FF, Mariani A. Risk factors for developing multiple malignancies in patients with endometrial cancer. *Int J Gynecol Cancer* 2011; **21**: 896-901 [PMID: 21666488 DOI: 10.1097/IGC.0b013e318219711f]

82 NIH Surveillance Research Program. SEER Stat Fact Sheets – Cancer of the Ovary. [accessed 2015 May 28].Available from: URL: http://seer.cancer.gov/statfacts/html/ovary.html

83 **Bhoola S**, Hoskins WJ. Diagnosis and management of epithelial ovarian cancer. *Obstet Gynecol* 2006; **107**: 1399-1410 [PMID: 16738170]

84 Ovarian Germ Cell Tumors Treatment (PDQ®): Health Professional Version. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-2015 Jul 10 [PMID: 26389449]

85 **Zalel Y**, Piura B, Elchalal U, Czernobilsky B, Antebi S, Dgani R. Diagnosis and management of malignant germ cell ovarian tumors in young females. *Int J Gynaecol Obstet* 1996; **55**: 1-10 [PMID: 8910077]

86 **Gutiérrez-Gutiérrez G**, Sereno M, Miralles A, Casado-Sáenz E, Gutiérrez-Rivas E. Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies. *Clin Transl Oncol* 2010; **12**: 81-91 [PMID: 20156778 DOI: 10.1007/S12094-010-0474-z]

87 **Stavraka C**, Ford A, Ghaem-Maghami S, Crook T, Agarwal R, Gabra H, Blagden S. A study of symptoms described by ovarian cancer survivors. *Gynecol Oncol* 2012; **125**: 59-64 [PMID: 22155797 DOI: 10.1016/j.ygyno.2011.12.421]

88 **Ezendam NP**, Pijlman B, Bhugwandass C, Pruijt JF, Mols F, Vos MC, Pijnenborg JM, van de Poll-Franse LV. Chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer survivors: results from the population-based PROFILES registry. *Gynecol Oncol* 2014; **135**: 510-517 [PMID: 25281491 DOI: 10.1016/j.ygyno.2014.09.016]

89 **Teng FF**, Kalloger SE, Brotto L, McAlpine JN. Determinants of quality of life in ovarian cancer survivors: a pilot study. *J Obstet Gynaecol Can* 2014; **36**: 708-715 [PMID: 25222166]

90 **Gangi A**, Cass I, Paik D, Barmparas G, Karlan B, Dang C, Li A, Walsh C, Rimel BJ, Amersi FF. Breast cancer following ovarian cancer in BRCA mutation carriers. *JAMA Surg* 2014; **149**: 1306-1313 [PMID: 25372568 DOI: 10.1001/jamasurg.2014.1081]

91 Practice Bulletin No. 140: management of abnormal cervical cancer screening test results and cervical cancer precursors. *Obstet Gynecol* 2013; **122**: 1338-1367 [PMID: 24264713 DOI: 10.1097/01.AOG.0000438960.31355.9e]

92 NIH Surveillance Research Program. SEER Stat Fact Sheets – Cancer of the Cervix Uteri. [accessed 2015 June 3]. Available from: URL: http://seer.cancer.gov/statfacts/html/cervix.html

93 **Ye S**, Yang J, Cao D, Lang J, Shen K. A systematic review of quality of life and sexual function of patients with cervical cancer after treatment. *Int J Gynecol Cancer* 2014; **24**: 1146-1157 [PMID: 25033255 DOI: 10.1097/IGC.0000000000000207]

94 **Akers AY**, Newmann SJ, Smith JS. Factors underlying disparities in cervical cancer incidence, screening, and treatment in the United States. *Curr Probl Cancer* 2007; **31**: 157-181 [PMID: 17543946]

95 **Le Borgne G**, Mercier M, Woronoff AS, Guizard AV, Abeilard E, Caravati-Jouvenceaux A, Klein D, Velten M, Joly F. Quality of life in long-term cervical cancer survivors: a population-based study. *Gynecol Oncol* 2013; **129**: 222-228 [PMID: 23280088 DOI: 10.1016/j.ygyno.2012.12.033]

96 **Harding Y**, Ooyama T, Nakamoto T, Wakayama A, Kudaka W, Inamine M, Nagai Y, Ueda S, Aoki Y. Radiotherapy- or radical surgery-induced female sexual morbidity in stages IB and II cervical cancer. *Int J Gynecol Cancer* 2014; **24**: 800-805 [PMID: 24662133 DOI: 10.1097/IGC.0000000000000112]

97 **Ploch E**. Hormonal replacement therapy in patients after cervical cancer treatment. *Gynecol Oncol* 1987; **26**: 169-177 [PMID: 2433195]

98 **Abu-Rustum NR**, Neubauer N, Sonoda Y, Park KJ, Gemignani M, Alektiar KM, Tew W, Leitao MM, Chi DS, Barakat RR. Surgical and pathologic outcomes of fertility-sparing radical abdominal trachelectomy for FIGO stage IB1 cervical cancer. *Gynecol Oncol* 2008; **111**: 261-264 [PMID: 18708244 DOI: 10.1016/j.ygyno.2008.07.002]

99 **Pareja R**, Rendón GJ, Sanz-Lomana CM, Monzón O, Ramirez PT. Surgical, oncological, and obstetrical outcomes after abdominal radical trachelectomy - a systematic literature review. *Gynecol Oncol* 2013; **131**: 77-82 [PMID: 23769758 DOI: 10.1016/j.ygyno.2013.06.010]

100 **Ramirez PT**, Schmeler KM, Soliman PT, Frumovitz M. Fertility preservation in patients with early cervical cancer: radical trachelectomy. *Gynecol Oncol* 2008; **110**: S25-S28 [PMID: 18501409 DOI: 10.1016/j.ygyno.2008.03.025]

101 **Shou H**, Chen Y, Chen Z, Zhu T, Ni J. Laparoscopic ovarian transposition in young women with cervical squamous cell carcinoma treated by primary pelvic irradiation. *Eur J Gynaecol Oncol* 2015; **36**: 25-29 [PMID: 25872330]

102 **Al-Badawi IA**, Al-Aker M, AlSubhi J, Salem H, Abduljabbar A, Balaraj K, Munkarah A. Laparoscopic ovarian transposition before pelvic irradiation: a Saudi tertiary center experience. *Int J Gynecol Cancer* 2010; **20**: 1082-1086 [PMID: 20683422 DOI: 10.1111/IGC.0b013e3181e2ace5]

103 **Balamurugan A**, Ahmed F, Saraiya M, Kosary C, Schwenn M, Cokkinides V, Flowers L, Pollack LA. Potential role of human papillomavirus in the development of subsequent primary in situ and invasive cancers among cervical cancer survivors. *Cancer* 2008; **113**: 2919-2925 [PMID: 18980275 DOI: 10.1002/cncr.23746]

104 **Rodriguez AM**, Kuo YF, Goodwin JS. Risk of colorectal cancer among long-term cervical cancer survivors. *Med Oncol* 2014; **31**: 943 [PMID: 24696219 DOI: 10.1007/s12032-014-0943-2]

105 **Underwood JM**, Rim SH, Fairley TL, Tai E, Stewart SL. Cervical cancer survivors at increased risk of subsequent tobacco-related malignancies, United States 1992-2008. *Cancer Causes Control* 2012; **23**: 1009-1016 [PMID: 22588679 DOI: 10.1007/s10552-012-9957-2]

106 NIH Surveillance Research Program. SEER Stat Fact Sheets – Cancer of the Vulva. [accessed 2015 May 31]. Available from: URL: http://seer.cancer.gov/statfacts/html/vulva.html

107 **Joura EA**, Lösch A, Haider-Angeler MG, Breitenecker G, Leodolter S. Trends in vulvar neoplasia. Increasing incidence of vulvar intraepithelial neoplasia and squamous cell carcinoma of the vulva in young women. *J Reprod Med* 2000; **45**: 613-615 [PMID: 10986677]

108 **Aerts L**, Enzlin P, Vergote I, Verhaeghe J, Poppe W, Amant F. Sexual, psychological, and relational functioning in women after surgical treatment for vulvar malignancy: a literature review. *J Sex Med* 2012; **9**: 361-371 [PMID: 22082135 DOI: 10.1111/j.1743-6109.2011.02520.x]

109 **Günther V**, Malchow B, Schubert M, Andresen L, Jochens A, Jonat W, Mundhenke C, Alkatout I. Impact of radical operative treatment on the quality of life in women with vulvar cancer--a retrospective study. *Eur J Surg Oncol* 2014; **40**: 875-882 [PMID: 24746935 DOI: 10.1016/j.ejso.2014.03.027]

110 **Kunos C**, Simpkins F, Gibbons H, Tian C, Homesley H. Radiation therapy compared with pelvic node resection for node-positive vulvar cancer: a randomized controlled trial. *Obstet Gynecol* 2009; **114**: 537-546 [PMID: 19701032 DOI: 10.1097/AOG.0b013e3181b12f99]

111 **Berger J**, Scott E, Sukumvanich P, Smith A, Olawaiye A, Comerci J, Kelley JL, Beriwal S, Huang M. The effect of groin treatment modality and sequence on clinically significant chronic lymphedema in patients with vulvar carcinoma. *Int J Gynecol Cancer* 2015; **25**: 119-124 [PMID: 25415076 DOI: 10.1097/IGC.0000000000000311]

112 **McCann GA**, Cohn DE, Jewell EL, Havrilesky LJ. Lymphatic mapping and sentinel lymph node dissection compared to complete lymphadenectomy in the management of early-stage vulvar cancer: A cost-utility analysis. *Gynecol Oncol* 2015; **136**: 300-304 [PMID: 25478927 DOI: 10.1016/j.ygyno.2014.11.079]

**P-Reviewer:** Kwon JS **S-Editor:** Ji FF **L-Editor: E-Editor:**